Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants

被引：24

作者：

Vogel, AM

Lennon, DR

Broadbent, R

Byrnes, CA

Grimwood, K

Mildenhall, L

Richardson, V

Rowley, S

机构：

[1] Univ Auckland, Wellington, New Zealand

[2] Paediat Soc New Zealand, Infect Dis & Immunisat Comm, Wellington, New Zealand

[3] Paediat Soc New Zealand, Fetus & Newborn Comm, Wellington, New Zealand

[4] Paediat Soc New Zealand, Resp Comm, Wellington, New Zealand

来源：

JOURNAL OF PAEDIATRICS AND CHILD HEALTH | 2002年 / 38卷 / 06期

关键词：

consensus; cost effectiveness; palivizumab; preterm; respiratory syncytial virus;

D O I：

10.1046/j.1440-1754.2002.00057.x

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Palivizumab prophylaxis significantly reduces hospitalization for respiratory syncytial virus (RSV) disease in preterm infants. However, palivizumab is very expensive. Data from a New Zealand cost-effectiveness analysis were considered by representatives of the Infectious Diseases and Immunisation, Fetus and Newborn, and Respiratory Committees of the Paediatric Society of New Zealand. Prophylaxis in all high-risk groups was associated with net cost. The consensus panel recommends that the priority for palivizumab be given to babies discharged on home oxygen with chronic lung disease, followed by babies born at 28 weeks or less gestation.

引用

页码：550 / 554

页数：5

共 50 条

[21] Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria
Resch, Bernhard
Gusenleitner, Walter
Nuijten, Mark J. C.
Lebmeier, Maximilian
Wittenberg, Wolfgang
CLINICAL THERAPEUTICS, 2008, 30 (04) : 749 - 760
[22] Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
Gaetano Chirico
Roberto Ravasio
Urbano Sbarigia
Italian Journal of Pediatrics, 35
[23] Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants
Pedraz, C
Carbonell-Estrany, X
Figueras-Aloy, J
Quero, J
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (09) : 823 - 827
[24] Respiratory syncytial virus immunoprophylaxis in high-risk infants with heart disease
Alexander, Peta M. A.
Eastaugh, Lucas
Royle, Jenny
Daley, Andrew J.
Shekerdemian, Lara S.
Penny, Daniel J.
JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2012, 48 (05) : 395 - 401
[25] Incidence of respiratory syncytial virus-related hospitalizations in high-risk children:: Follow-up of a national cohort of infants treated with palivizumab as RSV prophylaxis
Lacaze-Masmonteil, T
Rozé, JC
Fauroux, B
PEDIATRIC PULMONOLOGY, 2002, 34 (03) : 181 - 188
[26] Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden
Neovius, Kristian
Buesch, Katharina
Sandstrom, Kristina
Neovius, Martin
ACTA PAEDIATRICA, 2011, 100 (10) : 1306 - 1314
[27] Clinical and Pharmacological Aspects of Immunoprophylaxis for Respiratory Syncytial Virus Infection in High-Risk Infants
Lanari, Marcello
Silvestri, Michela
Rossi, Giovanni A.
CURRENT DRUG METABOLISM, 2013, 14 (02) : 216 - 225
[28] Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial
Carbonell-Estrany, Xavier
Simoes, Eric A. F.
Dagan, Ron
Hall, Caroline B.
Harris, Brian
Hultquist, Micki
Connor, Edward M.
Losonsky, Genevieve A.
PEDIATRICS, 2010, 125 (01) : E35 - E51
[29] Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab
Reeve, Carole A.
Whitehall, John S.
Buettner, Petra G.
Norton, Robert
Reeve, David M.
Francis, Fleur
JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2006, 42 (05) : 253 - 258
[30] Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)
Geskey, Joseph M.
Thomas, Neal J.
Brummel, Gretchen L.
BIOLOGICS-TARGETS & THERAPY, 2007, 1 (01) : 33 - 43

← 1 2 3 4 5 →